NW-3509
NW-3509 is an innovative new chemical entity which originates from Newron’s Ion Channel program. It modulates neuronal hyper-excitability and has shown activity in vivo in a broad range of psychosis, mania, anxiety, cognition and depression animal models.
NW-3509, acting by a different mechanism from current antipsychotics, has the potential to address unmet medical needs in schizophrenia such as cognitive symptoms, negative symptoms, mood disorders, partial responders, suicidality and co-morbidities such as anxiety and depression.
Furthermore, NW-3509 has the potential to treat the manic as well as the depressive phase of Bipolar Disorders without inducing sedation.
In August 2011 Newron received an IND approval from the FDA as an add-on to antipsychotics for patients with psychosis.
On 15 January 2015 Newron announced the completion of the first in man US Phase I study. NW-3509 was well-tolerated at all doses.